

## First reports of adverse drug reactions

© Springer Nature Switzerland AG 2018

Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by *Reactions Weekly*, the Adis drug safety newsletter. *Reactions Weekly* provides summaries of

adverse drug reaction news sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.

**Table 1** First published reports of adverse drug reactions recently identified by *Reactions Weekly*

Drug and adverse reaction	References
Infigratinib: hypoglycaemic episodes	Tella SH, Pablo FV, Sedmak C, et al. Effect of BGI398 on insulin sensitivity in a patient with tumor-induced osteomalacia [abstract no. SAT-150]. <i>Endocr Rev</i> 2018;39(2 Suppl). <a href="https://www.endocrine.org/meetings/endo-annual-meetings/abstract-details?ID=5882">https://www.endocrine.org/meetings/endo-annual-meetings/abstract-details?ID=5882</a>
Lutetium-(177lu)-oxodotreotide: acute pancreatitis (serious)	Karfis I, Marin G, MacHiels G, et al. Acute pancreatitis following peptide receptor radionuclide therapy: an unusual adverse event. <i>Clin Nucl Med</i> . 2018;43(7):e232–3. <a href="https://doi.org/10.1097/rlu.0000000000002118">https://doi.org/10.1097/rlu.0000000000002118</a>
Memantine: manic episode	Duan J, Lao C, Chen J, et al. Memantine induces manic episode in a 73-year-old patient with vascular neurocognitive disorder: a case report. <i>Neuropsychiatr Dis Treat</i> . 2018;14:1395–8. <a href="https://doi.org/10.2147/ndt.s160832">https://doi.org/10.2147/ndt.s160832</a>
Methylprednisolone: Takotsubo cardiomyopathy (serious)	Candilio L, Moon T, Sado D, et al. Iatrogenic corticosteroids induced Takotsubo cardiomyopathy. <i>Cardiovasc Revasc Med</i> . 2018;19(4):471–3. <a href="https://doi.org/10.1016/j.carrev.2017.09.013">https://doi.org/10.1016/j.carrev.2017.09.013</a>
Nepafenac: allergic urticaria	Yasar E, Kara DO, Yildirim N. A case of allergic urticaria after ophthalmic nepafenac use. <i>Turk J Ophthalmol</i> . 2018;48(3):146–9. <a href="https://doi.org/10.4274/tjo.78614">https://doi.org/10.4274/tjo.78614</a>
Osimertinib: toxic epidermal necrolysis (serious)	Wang J, Cheng XY, Lu Y, et al. A case report of toxic epidermal necrolysis associated with AZD-9291. <i>Drug Des Dev Ther</i> . 2018;12:2163–7. <a href="https://doi.org/10.2147/dddt.s168248">https://doi.org/10.2147/dddt.s168248</a>
Pirfenidone: cutaneous lupus erythematosus (serious)	Kelly AS, De la Harpe Golden P, D'Arcy C, et al. Drug-induced lupus erythematosus secondary to pirfenidone. <i>Br J Dermatol</i> . 2018;178(6):1437–8. <a href="https://doi.org/10.1111/bjd.16246">https://doi.org/10.1111/bjd.16246</a>
Pirfenidone: drug induced hypersensitivity syndrome (serious)	Suda K, Kamiya K, Chiang B, et al. A rare case of drug-induced hypersensitivity syndrome by pirfenidone for idiopathic pulmonary fibrosis. <i>Allergol Int</i> . 2018;67(3):425–6. <a href="https://doi.org/10.1016/j.alit.2018.02.010">https://doi.org/10.1016/j.alit.2018.02.010</a>

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage